ABOUT US | EXPERTISE
ABOUT US | EXPERTISE
Our executive committee, board of directors, and scientific advisory board are comprised of accomplished drug hunters and experts in the biotechnology and pharmaceutical industries.
Executive Committee
- Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation. (Press Release, April 4, 2025).
- Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®. (Press Release, October 5, 2025).